{"nctId":"NCT01435460","briefTitle":"AlrexÂ® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)","startDateStruct":{"date":"2010-08"},"conditions":["Seasonal Allergic Conjunctivitis"],"count":300,"armGroups":[{"label":"Alrex","type":"EXPERIMENTAL","interventionNames":["Drug: Loteprednol etabonate 0.2%"]},{"label":"Patanol","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Olopatadine 0.1%"]}],"interventions":[{"name":"Loteprednol etabonate 0.2%","otherNames":["Alrex"]},{"name":"Olopatadine 0.1%","otherNames":["Patanol"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who are diagnosed with acute SAC and experience at least grade 4 ocular itching and at least grade 2 bulbar conjunctival injection (redness) in each eye due to seasonal allergy at Visit 1.\n\nExclusion Criteria:\n\n* Subjects who have a known hypersensitivity to the study medications or their components or contraindications to ocular corticosteroids.\n* Subjects who use any of the disallowed medications throughout the duration of the study and during the period indicated prior to Visit 1.\n* Subjects who have intraocular pressure (IOP) greater than 21 mm Hg in either eye or any type of glaucoma.\n* Subjects who have a history of any severe/serious ocular pathology or medical condition that could result in the subject's inability to complete the study or affect the subject's safety or trial parameters.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Bulbar Conjunctival Injection","description":"Bulbar conjunctival injection (sign) evaluated using a grading scale from 0-3: where 0 = Absent and 3 = Severe","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.91","spread":"0.521"},{"groupId":"OG001","value":"-1.71","spread":"0.585"}]}]}]},{"type":"PRIMARY","title":"Ocular Itching","description":"Ocular itching (symptom) evaluated using a grading scale from 0-4 where 0 = Absent and 4 = Severe","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.74","spread":"0.469"},{"groupId":"OG001","value":"-3.28","spread":"0.908"}]}]}]},{"type":"SECONDARY","title":"Bulbar Conjunctival Injection","description":"Bulbar conjunctival injection (sign) evaluated using a grading scale from 0-3: where 0 = Absent and 3 = Severe","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.36","spread":"0.569"},{"groupId":"OG001","value":"-1.18","spread":"0.610"}]}]}]},{"type":"SECONDARY","title":"Ocular Itching","description":"Ocular itching (symptom) evaluated using a grading scale from 0-4 where 0 = Absent and 4 = Severe","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.46","spread":"0.876"},{"groupId":"OG001","value":"-2.02","spread":"0.851"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":151},"commonTop":[]}}}